METHOD FOR TREATMENT OF ALLERGIC RESPIRATORY TRACT DISEASE (AAD)/ASTHMA Russian patent published in 2023 - IPC A61K35/28 A61K35/545 C12N5/775 A61P11/06 A61P27/14 

FIELD: medicine.

SUBSTANCE: invention relates to medicine, namely to a method for treating a disease in a subject selected from a group: allergic respiratory tract disease (AAD) and asthma. The method for treatment in the subject of the disease selected from the group: allergic respiratory tract disease (AAD) and asthma includes the introduction of mesenchymoangioblastic mesenchymal stem cell (MCA-MSC) to the subject, where MCA-MSC expresses miR-145-5p, miR-181b-5p and miR-214-3p, but not miR-127-3p and miR-299-5p, where MCA-MSC has the phenotype CD73+CD105+CD90+CD146+CD44+CD10+CD31-CD45-, where MCA-MSC in an amount from 10⁶ MCA-MSC/kg to 2×10⁸ MCA-MSC/kg is administered by the method selected from intravenous and intranasal; and where MCA-MSC was obtained by a method including: cultivation of a primary mesodermal cell differentiated from an induced pluripotent stem cell (iPSC) in a medium for the formation of a mesenchymal colony (M-CFM) containing LiCl and FGF2 (fibroblast growth factor), but not containing PDGF (platelet growth factor), under normal conditions of oxygen content, for a time sufficient for the formation of a mesenchymal colony; and cultivation of a mesenchymal colony in an attached state to obtain MCA-MSC.

EFFECT: method described above makes it possible to effectively treat allergic diseases of the respiratory tract and asthma.

18 cl, 11 dwg, 8 tbl, 6 ex